RAD-140 at a glance
A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.
RAD-140 (Testolone) is a non-steroidal selective androgen receptor modulator developed by Radius Health. It demonstrates one of the highest anabolic-to-androgenic selectivity ratios of any SARM studied - in animal models it has outperformed testosterone in stimulating muscle growth at doses that produce no prostate stimulation.
In a primate study, RAD-140 increased lean mass significantly with no prostate growth and no liver toxicity at effective doses. Phase 1 and 2 clinical trials in breast cancer (AR+/ER+ metastatic) have demonstrated partial responses and disease stabilization, with manageable side effects. Testosterone suppression is significant at doses used in performance settings (10-20mg), requiring post-cycle therapy.
A distinctive feature of RAD-140 versus other SARMs is its neuroprotective activity: it activates MAPK/PI3K/Akt signaling in neurons, reducing Alzheimer's-related amyloid beta toxicity and neuronal apoptosis in preclinical models. This dual anabolic/neuroprotective profile has generated significant scientific interest. It remains unapproved for any indication outside of oncology trials and is WADA-banned.
Key Benefits
Saves this peptide to your Watchlist and helps you find new research, news, and questions later.